Does Ozempic Affect Bone Density?
GLP-1 medications may affect bone mineral density as a consequence of rapid weight loss rather than a direct drug effect. Reduced mechanical load from lower body weight, combined with decreased calcium, vitamin D, and magnesium intake from reduced food consumption, creates measurable bone density risk particularly in women over 40. Resistance exercise is the most evidence-backed non-pharmacological intervention for maintaining bone density during GLP-1 treatment.
GLP-1 Resource Center
Does Ozempic affect bone density?
Bone density loss during GLP-1 treatment is an emerging concern that most patients are never warned about. Rapid weight loss of any kind is associated with reduced bone mineral density, and GLP-1 medications accelerate weight loss faster than most other interventions.
The evidence
A 2023 analysis of GLP-1 medication trials found modest reductions in bone mineral density markers in some patient groups during treatment. The concern is not specific to GLP-1 medications. It is a consequence of rapid weight loss itself. Research shows that bone mineral density may decrease during active caloric restriction in the absence of specific bone-protective interventions. GLP-1 medications, which produce weight loss of 15 to 22% over 12 to 18 months, compress this loss into a much shorter timeframe.
Why nutritional depletion compounds the risk
Calcium and vitamin D are the primary nutritional inputs for bone mineral density maintenance. Research published in Obesity Reviews in 2026 confirmed that caloric intake drops 16 to 39% during GLP-1 treatment, meaning calcium and vitamin D intake may drop alongside it. A National Institutes of Health analysis found that approximately 42% of Americans are already vitamin D deficient. GLP-1-related reduced food intake may compound an already widespread deficit. Magnesium depletion, common during GLP-1 treatment, may impair the body's ability to use calcium effectively for bone maintenance regardless of calcium intake.
Who is most at risk
Women over 40 on GLP-1 medications are at highest risk. Women lose approximately 1% of bone density per year after age 40, accelerating to 2 to 3% per year during menopause. Rapid weight loss compounding that trajectory warrants proactive attention. Discuss DEXA scanning with your healthcare provider if you are over 40 and experiencing significant weight loss on GLP-1 medications.
What the evidence supports
Adequate calcium intake, vitamin D supplementation, magnesium, and resistance exercise are the evidence-backed interventions for supporting bone density during periods of rapid weight loss. Resistance exercise is the most important. Studies show it can help maintain bone density even during significant caloric restriction.
The TAKE approach
TAKE Complete delivers vitamin D, calcium, magnesium, and zinc in bioavailable forms calibrated for GLP-1 patients. TAKE Hydrate provides magnesium and potassium to support calcium metabolism. Both are included in The Foundation System.
These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider about bone health monitoring during GLP-1 treatment.